Issue 3

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation

Jesper Gunst, Kathrine Kjær, Rikke Olesen, Thomas Rasmussen, Lars Østergaard, Paul Denton, Ole Søgaard, Martin Tolstrup

Read More

Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials

Kimberly Struble, Kirk Chan-Tack, Karen Qi, Thamban Valappil, Sarah Connelly, Poonam Mishra, Dionne Price, Jeffrey Murray, Debra Birnkrant

Read More

Evaluation of clinicians’ knowledge of and attitudes to Ebola virus disease in Ebonyi State, Nigeria

Nnennaya Ajayi, Chiedozie Ojide, Immanuel Ajayi, Kingsley Ukwaja

Read More

What is the effect of self-identified HIV activism in willingness to participate in HIV cure-related clinical trials? Results from the ANRS-APSEC study

Marion Fiorentino, Christel Protière, Luis Sagaon-Teyssier et al.

Read More

HIV-1 elite controllers: an immunovirological review and clinical perspectives

Nour Gebara, Vanessa El Kamari, Nesrine Rizk

Read More

Statistical analysis of single-copy assays when some observations are zero

Peter Bacchetti, Ronald Bosch, Eileen Scully, Xutao Deng, Michael Busch, Steven Deeks, Sharon Lewin

Read More

Back to top